Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02587598 · OUTCOME

Pharmacokinetics: Tmax of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib

Study of INCB053914 in Subjects With Advanced Malignancies · Source last updated 2021-12-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
h
Interval / dispersion
Full Range
Time frame
Regimen 2 Week 4

Groups in this outcome

Parts 3 & 4: INB053914 80 mg BID + Ruxolitinib

Combination Treatment Group C: INCB053914 80 mg BID + Ruxolitinib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Parts 3 & 4: INB053914 80 mg BID + Ruxolitinib6

Reported measurements

Source class 1
Values in h · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Parts 3 & 4: INB053914 80 mg BID + Ruxolitinib2.02Not reported14Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1
        upper Limit
        4
        value
        2.02
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    units
    Participants
dispersion Type
Full Range
groups
  1. description
    Combination Treatment Group C: INCB053914 80 mg BID + Ruxolitinib
    id
    OG000
    title
    Parts 3 & 4: INB053914 80 mg BID + Ruxolitinib
param Type
MEDIAN
reporting Status
POSTED
time Frame
Regimen 2 Week 4
title
Pharmacokinetics: Tmax of Combination Treatment Group C INCB053914 80 mg + Ruxolitinib
type
SECONDARY
unit Of Measure
h

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice